Search
Close this search box.
Product Updates

Update on Detection of the latest SARS-CoV-2 Variant

Singapore, August 15, 2023 – Update on Detection of the Latest SARS-CoV-2 Variant

Credo Diagnostics Biomedical Pte Ltd is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method, comparing primers and probes of the assays involving SARS-CoV-2 virus detection to all sequences listed in GISAID up till August 11th, 2023.

We are pleased to announce that the VitaPCR™ system is capable of detecting the Omicron EG.5 and its subvariants EG.5.1, and our analysis has confirmed that the performance of our SARS-CoV-2 RNA detection assays* is not impacted by the Omicron subvariant EG.5 and its descendent lineages.

*The SARS-CoV-2 RNA detection assays include:
.VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
.VitaPCR™ SARS-CoV-2 Assay (PCRAE0114)
.VitaPCR™ SARS-CoV-2 Gen 2 Assay (PCRAE0120)

For more information, contact us at service@credodxbiomed.com.

Share:

Latest Posts

Send us a message